Clinical Trials Directory

Trials / Completed

CompletedNCT00712686

Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia

A Multicenter, Double-Blind, Randomized, Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
690 (actual)
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia

Conditions

Interventions

TypeNameDescription
DRUGAripiprazoleTablets, Oral, 15-30 mg, once daily, 140 weeks
DRUGOlanzapineCapsule, Oral, 10-20 mg, once daily, 140 weeks

Timeline

Start date
2000-06-01
Primary completion
2003-12-01
Completion
2003-12-01
First posted
2008-07-10
Last updated
2013-11-08

Source: ClinicalTrials.gov record NCT00712686. Inclusion in this directory is not an endorsement.